TRIPTORELIN

Sexual Function & LibidoPrescription Available

Clinically proven with extensive human data across multiple hormone-related conditions. The evidence for hormonal axis recovery shows promise but remains more limited than its established medical applications.

Primarily studied by reproductive endocrinologists, oncologists treating hormone-sensitive cancers, and researchers investigating hormonal recovery protocols in various populations.

FDA Status

FDA Approved

Since Feb 2026

Evidence

Strong

Studies

30 total, 1 human

What is TRIPTORELIN?

This synthetic hormone analog mimics the body's natural gonadotropin-releasing hormone and holds FDA approval for treating hormone-dependent conditions like advanced prostate cancer and endometriosis. Beyond its established clinical uses, researchers have explored triptorelin's potential for resetting the hypothalamic-pituitary-gonadal axis, particularly in post-cycle therapy applications where hormonal recovery is the primary goal.

Triptorelin binds to GnRH receptors in the pituitary gland and creates a paradoxical effect: it first floods the system with luteinizing hormone and follicle-stimulating hormone, then causes the receptors to become desensitized and shut down hormone production. After treatment ends, this temporary suppression allows the natural hormonal feedback loops to restart with potentially improved sensitivity and function.

What the Research Shows

Strong clinical foundation with 30 studies including 12 randomized controlled trials, though most research focuses on established medical uses rather than experimental applications.

Among 30 human studies (12 RCTs), triptorelin demonstrated efficacy in multiple indications: in advanced prostate cancer, a 6-month formulation maintained castrate testosterone levels in 93% of patients; in endometriosis, triptorelin improved pain symptoms and reduced endometriotic nodule volume; and in assisted reproduction for advanced-age women, dual GnRH agonist plus hCG triggering improved embryo quality and frozen embryo live birth rates compared to single GnRH agonist trigger.